CDK7/9-IN-1

Cat. No.:	HY-145408
CAS No.:	2747919-19-1
Molecular Formula:	$C_{24}H_{32}F_3N_5O_2$
Molecular Weight:	479.54
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC_{50}s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC_{50} of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer[1].	
IC_{50} & Target	CDK7 5.74-65.6 nM (IC_{50})	CDK9 2.14 μM (IC_{50})
In Vitro	CDK7/9-IN-1 (example 8; 0.001-20 μM; 4 h) inhibits CDK7 with an relative IC_{50} of 0.0262 μM for phospho-carboxyl terminal domain (Rbp2) (Ser5) in HCT116 cells[1]. CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits CDK9 with an IC_{50} of 2.59 μM for phospho-carboxyl terminal domain (Rbp2) (Ser2) in HCT116 cells[1]. CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits cMyc with an relative IC_{50} of 0.0138 μM in HCT116 cells[1]. CDK7/9-IN-1 (20 μM, 2 μM, and 0.2 μM; 1 h) shows excellent selectivity against the 468 protein kinases panel. CDK7/9-IN-1 shows approximately 96% inhibition against CDK7[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Maria Carmen FERNANDEZ FIGUEROA, et al. Compounds useful for inhibiting cdk7. WO2021242602 A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA